Arylamine N-acetyltransferases - of mice, men and microorganisms

Trends in Pharmacological Sciences

Volumn 22, Issue 3, 2001, Pages 140-146

  Upton, Anna ^a   Johnson, Nichola ^a   Sandy, James ^a   Sim, Edith ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; ASPARTIC ACID; CARCINOGEN; CYSTEINE; HISTIDINE; HYDRAZINE; ISONIAZID;

ALLELE; ARTICLE; CATALYSIS; DNA POLYMORPHISM; DRUG INACTIVATION; DRUG RESPONSE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME STRUCTURE; ENZYME SUBUNIT; GENETIC CODE; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TRANSPORT; XENOBIOTIC METABOLISM;

EID: 0035282779     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01639-4     Document Type: Review

References (75)

1. Arylamine N-acetyltransferases
2. Genetic control of isoniazid acetylation in man
3. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms
4. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer
5. Update on consensus arylamine N-acetyltransferase gene nomenclature
6. International collaborative study on genetic susceptibility to environmental carcinogens
7. Partial purification and properties of the isoniazid transacetylase in human liver: Its relationship to the acetylation of p-aminosalicylic acid
8. Cloning and characterisation of arylamine N-acetyltransferase genes of M. smegmatis and M. tuberculosis; increased expression results in isoniazid resistance
9. Characterisation of Eubacterial arylamine N-acetyltransferases - Identification and comparison of eighteen members of the protein family with conserved active site cysteine, histidine and aspartate residues
10. Evidence for arylamine N-acetyltransferase activity in the bacterium Helicobacter pylori
11. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
12. Acetyl-coenzyme A: Arylamine N-acetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituents on the rate
13. Arylamine N-acetyltransferase from chicken liver
14. N-acetylation pharmacogenetics: A gene deletion causes absence of arylamine N-acetyltransferase in liver of slow acetylator rabbits
15. Deficiency of cytosolic arylamine N-acetylation in the domestic cat and wild felids caused by the presence of a single NAT1-like gene
16. Bovine Arylamine N-acetyltransferase
17. An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes
18. Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells
19. Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes
20. Involvement of Cys 69 in the catalytic mechanism of NhoA of Salmonella typhimurium
21. Lessons from the rifamycin biosynthetic gene cluster
22. On the active site of liver acetyl-CoA arylamine N-acetyltransferase from rapid acetylator rabbits (III/J)
23. Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in E. coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2
24. Study of the role of the highly conserved residues Arg9 and Arg64 in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis
25. Structure of arylamine N-acetyltransferase reveals a catalytic triad
26. The first 3D structure of arylamine N-acetyltransferase reveals a protease-like catalytic triad
27. A fragment consisting of the first 204 amino-terminal amino acids of human arylamine N-acetyltransferase one (NAT1) and the first transacetylation step of catalysis
28. Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2
29. Overexpression and large-scale purification of recombinant hamster polymorphic arylamine N-acetyltransferase as a dihydrofolate reductase fusion protein
30. N-acetyltransferase genetics and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis
31. Identification and characterisation of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe
32. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: Functional and localization studies
33. Expression of arylamine N-acetyltransferase in human intestine
34. Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours
35. Human arylamine N-acetyltransferase genes: Isolation, chromosomal localisation and functional expression
36. Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases
37. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases of human liver
38. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: Association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue
39. 560A mutations
40. Genotyping human arylamine N-acetyltransferase type 1 (NAT1). The identification of two novel allelic variants
41. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1)
42. Placental expression of arylamine N-acetyltransferases: Evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2
43. Characterisation of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1
44. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk
45. Slow acetylation in mice is caused by a labile and catalytically impaired mutant N-acetyltransferase (NAT2*9)
46. Developmental expression of N-acetyltransferases in C57Bl/6 mice
47. Immunochemical detection of arylamine N-acetyltransferase during mouse embryonic development and in adult mouse brain
48. Linkage of Nat and Es-1 in the mouse and development of strains congenic for N-acetyltranserase
49. Chromosomal localisation and mapping of the genes for murine arylamine N-acetyltransferases (NATs), enzymes involved in the metabolism of carcinogens: Identification of a novel non-coding exon for Nat2
50. Characterisation of a hormone response element in the mouse N-acetyltransferase 2 (Nat2*) promoter
51. Tissue and gender specific expression of N-acetyltransferase 2 (NAT2*) during development of the outbred mouse strain CD-1
52. Arylamine N-acetyltransferase type 2 (NAT2), chromosome 8 aneuploidy, and identification of a novel NATI cosmid clone: An investigation in bladder cancer by interphase
53. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer
54. Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia
55. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk
56. N-acetyl transferase 1: Two polymorphisms in coding sequence identified in colorectal cancer patients
57. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: The influence of smoking
58. Molecular analysis of the N-acetyltransferase 1 gene (NAT1*) using polymerase chain reaction-restriction fragment-single strand conformation polymorphism assay
59. N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions
60. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid
61. N-acetyltransferase polymorphism. Comparison of genotype and phenotype in humans
62. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity
63. Pitfalls in N-acetyltransferase 2 genotyping
64. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: Evidence of a gene-gene-exposure three-way interaction
65. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk
66. Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas
67. Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas
68. Genotype/phenotype discordance for human arylamine N-acetyltrasferase (NAT2) reveals a new slow-acetylator allele common in African-Americans
69. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people
70. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer
71. Arylamine N-acetyltransferase 1 (NAT1) genotypes in a Lebanese population
72. Molecular mechanism of slow acetylation of drugs and carcinogens in humans
73. Diverse point mutations in the human gene for polymorphic N-acetyltransferase
74. Genotyping human polymorphic arylamine N-acetyltransferase: Identification of new slow allotypic variants
75. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene